Trials / Completed
CompletedNCT00768664
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
CLINICAL PHASE 2 MULTICENTER TRIAL OF PF-00299804 IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00299804 | 45 mg by continuous oral dosing |
Timeline
- Start date
- 2008-11-04
- Primary completion
- 2010-05-05
- Completion
- 2012-04-18
- First posted
- 2008-10-08
- Last updated
- 2021-02-09
- Results posted
- 2021-02-09
Locations
10 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00768664. Inclusion in this directory is not an endorsement.